Paper Details

  1. Home
  2. Paper Details

Low dose alpha interferon treatment in chronic hepatitis B virus infection.

Author: BaumgartenR, FenglerJ D, Hintsche-KilgerB, KleinH, MarkusR, MeiselH, MüllerR, SchulzM, WittenbergH, von WussowP

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

Interferon alfa-2b treatment for chronic viral hepatitis B resulted in complete response in one patient and partial response in 32% of treated patients, significantly higher than the spontaneous remission rate in the control group.
Paper Details　
Original Abstract of the Article :
Fifty eight patients with chronic viral hepatitis B (HBV) were randomised in a prospectively controlled trial. Thirty patients were treated with 3 million units (MU) of interferon alfa-2b subcutaneously thrice weekly for four months. Twenty eight controls received no treatment. The follow up period ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1136/gut.34.2_suppl.s97

データ提供：米国国立医学図書館（NLM）

Low Dose Alpha Interferon: A New Path in the Desert of Hepatitis B Treatment

The search for effective treatments for [chronic hepatitis B virus infection] is a long and often challenging journey, much like a camel caravan traversing a vast and unforgiving desert. This study, like a research expedition mapping out a new route, investigates the potential benefits of [low-dose alpha interferon treatment] for individuals with this debilitating condition. The research explores the drug's efficacy in controlling viral replication and improving liver function.

A Glimpse of Hope: Alpha Interferon's Potential to Control Hepatitis B

This research, like a caravan discovering a hidden oasis in the desert, suggests that [low-dose alpha interferon] may offer a potential new path for treating [chronic hepatitis B virus infection]. The findings indicate that this treatment could potentially lead to [a reduction in viral load and improved liver function], offering a glimmer of hope for individuals living with this challenging condition.

Navigating the Landscape: Assessing the Risks and Benefits

Like a camel caravan carefully navigating a complex and challenging desert landscape, it is crucial to weigh the potential risks and benefits of [alpha interferon treatment]. This research, like a careful examination of a map, highlights the importance of considering potential side effects and ensuring that the benefits outweigh the risks. Further research, much like a continued exploration of the desert, is needed to fully understand the long-term effects of this treatment and optimize strategies for managing chronic hepatitis B infection.

Dr.Camel's Conclusion

The research on low-dose alpha interferon for chronic hepatitis B virus infection offers a promising path forward, like a well-worn trail leading to a hidden oasis in a vast desert. This study suggests that this treatment could potentially reduce viral load and improve liver function, offering hope for individuals living with this debilitating condition. While further research is needed to fully understand its effectiveness and safety, this research provides a valuable contribution to the fight against chronic hepatitis B, much like a camel caravan discovering a new route through a challenging and unforgiving desert.

Date :
  1. Date Completed 1993-07-27
  2. Date Revised 2019-05-01
Further Info :

Pubmed ID

8314499

DOI: Digital Object Identifier

10.1136/gut.34.2_suppl.s97

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.